Investor Overview

Corporate Profile
vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.
Presentations
DateTitle
11/16/18
Download Documentation Investor Presentation
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
11/19/18vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 19, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that company management will present a corporate overview at the Piper Jaffray 30th Annual Healthcare Conference on Tuesday, Nov. 27, 2018 at 2:10 p.m. ET in New York City. A live webcast of the presentation can be accessed here and will be archived for 30 days following the presentation at www.vtvtherapeutics.com. vTv Therapeuti... 
Printer Friendly Version
11/08/18vTv Therapeutics Announces Third Quarter 2018 Results and Update
HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 8, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported financial results for the third quarter that ended September 30, 2018, and provided an update on recent achievements and upcoming events. “We continue to believe in the therapeutic potential of azeliragon and are committed to finding the optimal development pathway forward for the program,” said Steve Holcombe, chief executive officer, vTv... 
Printer Friendly Version
10/29/18vTv Therapeutics Announces Transfer of Listing to The Nasdaq Capital Market
HIGH POINT, N.C.--(BUSINESS WIRE)--Oct. 29, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease (AD) and diabetes, today announced that The NASDAQ Stock Market LLC (“Nasdaq”) has approved the Company’s application to list its Class A Common Stock on The Nasdaq Capital Market. The Company’s securities will be transf... 
Printer Friendly Version
10/24/18vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimer’s and Diabetes at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Subgroup Analysis Indicates Potential Benefit of Treatment with Azeliragon for Patients with Type 2 Diabetes and Alzheimer’s Disease Nearly 40 percent of Medicare Beneficiaries with Dementia Also Suffer from Diabetes, a Large Population to Potentially Benefit HIGH POINT, N.C.--(BUSINESS WIRE)--Oct. 24, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of ora... 
Printer Friendly Version
Webcasts
DateTitle
11/27/18
Download Documentation vTv Therapeutics Inc. at 30th Annual Piper Jaffray Healthcare Conference
Get help downloading or viewing the above file types
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.